Memo Therapeutics AG appoints Paul Carter as Chairperson
08 Julio 2024 - 1:00AM
Memo Therapeutics AG appoints Paul Carter as Chairperson
PRESS RELEASE
Memo Therapeutics AG appoints Paul Carter
as Chairperson
- Virology
and commercial expertise will support Phase III readiness and
commercial preparations of AntiBKV
-
Extensive public and private market experience following executive
positions in numerous biopharma companies
Schlieren / Zurich, Switzerland,
8 July, 2024 – Memo Therapeutics AG (or
“MTx”), a late-stage biotech company translating unique immune
responses into superior medicines to treat viral infections and
cancer, today announces the appointment of Paul Carter as
Chairperson of the Board of Directors.
Paul has had an extensive executive career in
the biopharma space, with commercial and M&A expertise spanning
North America, Europe, and Asia. He has over 10 years of experience
working in the virology field at Gilead Sciences Inc., most
recently as EVP and Chief Commercial Officer, where he oversaw over
$30 billion dollars of sales and contributed to multiple M&A
transactions. Prior to this, he spent seven years at
GlaxoSmithKline (“GSK”), where he was responsible for all GSK
interests in the Greater China region.
Paul will replace Elias Papatheodorou, who was
instrumental in the transition of MTx from a preclinical-stage to a
well-funded clinical-stage company with an experienced and
well-rounded management team. Elias is transitioning into an
executive role at a European biotech and will hand-over to Paul as
part of a planned succession process.
Erik van den Berg, CEO of MTx,
commented: “We are delighted to welcome Paul Carter as our
Chairperson. Paul’s track record and commercial and M&A
expertise make him a perfect addition to our team. We look forward
to his advice and support in driving the Company’s continued
success as we advance into a Phase III ready organization. To
Elias, we extend our gratitude for his significant contributions to
our company, culminating in our recently closed Series C
financing.”
Paul Carter, incoming Chairperson at
MTx, added: “I am thrilled to be taking on this role at
such a pivotal stage in MTx’s development. The Company’s AntiBKV
program shows tremendous promise, with Phase III trials fast
approaching. BKV remains a significant unmet need and I look
forward to working closely with the Board and management team on
realizing AntiBKV’s potential for kidney transplant patients
worldwide.”
Following his successful career as an executive,
Paul is now focused on his Board and retained Advisory roles. He is
currently a Board Member for a wide range of public companies
including HutchMed (Nasdaq/AIM:HCM; HKEX:13) and Immatics
(Nasdaq:IMTX), and has held prior Board roles at Alder
BioPharmaceuticals (Nasdaq:ALDR), acquired by Lundbeck (CPH:HLUN-A)
for $2 billion, and VectivBio (Nasdaq:VECT), acquired by Ironwood
Pharmaceuticals (Nasdaq: IRWD) for $1 billion.
In May, MTx announced that it had raised an
additional CHF 20 million, bringing in new investors Kurma Partners
and Ysios Capital and increasing its Series C financing to CHF 45
million.
-Ends-
Contacts |
|
Memo Therapeutics AG |
|
info@memo-therapeutics.com |
|
|
|
ICR Consilium |
Amber Fennell, Ashley Tapp |
memotx@consilium-comms.com |
+44 (0)20 3709 5700 |
About Memo Therapeutics AGMemo
Therapeutics AG (“MTx”) is a late-stage biotech company translating
unique immune responses into superior medicines through the
development of best-in-class antibodies to treat viral infections
and cancer. The Company’s lead program, AntiBKV, is in Phase II
development targeting BK viremia in kidney transplant recipients,
an infection which can result in decreased kidney functionality and
longevity and reduced patient survival. AntiBKV has the potential
to become the best and first-in-class BKV disease-modifying therapy
for kidney transplant patients with a market potential of more than
$1bn.
Alongside AntiBKV, MTx is focused on discovering
antibodies for novel oncology targets, both alone and in
partnership. The Company has a partnership in place with Ono
Pharmaceutical since late 2022. Underpinning MTx’s core assets is
its proprietary DROPZYLLA® technology, an antibody repertoire
copying engine with high- throughput screening capabilities. MTx is
a private company located in Schlieren / Zurich and backed by
investors including Ysios Capital, Kurma Partners, Pureos
Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.
Learn more at www.memo-therapeutics.com, and on LinkedIn.